CLRB
Cellectar Biosciences, Inc.
Key Financials
Net Income
$-21791037
↑ 51.1%
Operating Income
$-22979844
↑ 55.6%
EPS (Diluted)
$-8.35
↓ 496.4%
Total Assets
$15.0M
↓ 41.2%
Cash & Equivalents
$13.2M
↓ 43.3%
Total Liabilities
$5.1M
↓ 48.4%
Shareholders' Equity
$8.5M
↓ 40.3%
Long-term Debt
$330222.00
↓ 26.6%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| SCHEDULE 13G | 8/14/2026 | View on SEC |
| SCHEDULE 13G | 8/14/2026 | View on SEC |
| SCHEDULE 13G | 8/14/2026 | View on SEC |
| SCHEDULE 13G | 8/14/2026 | View on SEC |
| SCHEDULE 13G | 8/13/2026 | View on SEC |
| 8-K | 8/13/2026 | View on SEC |
| 10-Q | 8/13/2026 | View on SEC |
| SCHEDULE 13G | 8/4/2026 | View on SEC |
| 4/A | 7/10/2026 | View on SEC |
| 8-K | 7/10/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | CLRB |
| Company Name | Cellectar Biosciences, Inc. |
| CIK | 1279704 |
| Sector | Pharmaceutical Preparations |
| Industry | Non-accelerated filer Smaller reporting company |
| Exchange | Nasdaq |
| SIC Code | 2834 |
| SIC Description | Pharmaceutical Preparations |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| State of Incorporation | DE |
| Phone | (608) 441-8120 |